Drug Profile

IBR 900

Alternative Names: IBR-900

Latest Information Update: 23 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Imbioray (Hangzhou) Biomedicine
Developer Beijing Boren Hospital
Class Antineoplastics; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

09 Jun 2022 Imbioray (Hangzhou) Biomedicine plans a phase I trial for Liver cancer (Inoperable/Unresectable, Late-stage disease, Combination therapy) in June 2022 (IV, Injection) (NCT05411757)
24 Dec 2021 Phase-I/II clinical trials in Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT05271279)
24 Dec 2021 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT05271279)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com